Barclays’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-530
| Closed | -$1.38K | – | 5376 |
|
|
2025
Q4 | $1.38K | Hold |
530
| – | – | ﹤0.01% | 5070 |
|
|
2025
Q3 | $933 | Hold |
530
| – | – | ﹤0.01% | 5180 |
|
|
2025
Q2 | $737 | Sell |
530
-75
| -12% | -$98 | ﹤0.01% | 5068 |
|
|
2025
Q1 | $597 | Sell |
605
-1,808
| -75% | -$2.18K | ﹤0.01% | 5072 |
|
|
2024
Q4 | $3.16K | Sell |
2,413
-5,917
| -71% | -$17.6K | ﹤0.01% | 5084 |
|
|
2024
Q3 | $28.7K | Buy |
8,330
+7,800
| +1,472% | +$25.7K | ﹤0.01% | 4847 |
|
|
2024
Q2 | $1.75K | Hold |
530
| – | – | ﹤0.01% | 4655 |
|
|
2024
Q1 | $2.5K | Hold |
530
| – | – | ﹤0.01% | 4904 |
|
|
2023
Q4 | $3.87K | Sell |
530
-3,524
| -87% | -$19.7K | ﹤0.01% | 5045 |
|
|
2023
Q3 | $49K | Buy |
4,054
+645
| +19% | +$6.66K | ﹤0.01% | 3883 |
|
|
2023
Q2 | $36.1K | Buy |
+3,409
| New | +$35.1K | ﹤0.01% | 3969 |
|
|
2022
Q2 | – | Sell |
-77
| Closed | -$1K | – | 5215 |
|
|
2022
Q1 | $1K | Buy |
+77
| New | +$1.14K | ﹤0.01% | 4849 |
|
Barclays's RPTX Position: Q1 2026 in Review
Barclays sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 530 shares — an estimated $1.38K sold.
Barclays first reported a position in RPTX in Q1 2022 and held it in 12 quarters. The position peaked at $49K in Q3 2023. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Barclays reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Barclays sold 530 Repare Therapeutics shares in Q1 2026, an estimated $1.38K.
- Barclays first reported a position in Repare Therapeutics in Q1 2022 and held it in 12 quarters.
- Barclays's Repare Therapeutics position peaked at $49K in Q3 2023.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.